Loading clinical trials...

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy | Clinical Trials | Clareo Health

COMPLETEDNCT05621148

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy

Data evaluating and quantifying real-world outcomes of patients post-ibrutinib discontinuation, as well as outcomes of patients who have progressed on a Bruton tyrosine kinases inhibitors (BTKi) and r...

Lead sponsor: French Innovative Leukemia Organisation•8 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment152

Start dateJan 2023

Last updatedDec 3, 2025

Condition

CLL, Relapsed CLL, Refractory Bruton Tyrosine Kinase Inhibitor Small Lymphocytic Leukemia

Locations shown

CHU Estaing - Hématologie Clinique Adulte

Clermont-Ferrand

Centre Léon Bérard - Hématologie

Lyon

Institut Paoli-Calmettes - Hématologie Clinique

Marseille

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions